FT4

AustinPx Invests in Pharmaceutics and Manufacturing Capabilities to Accelerate Drug Development

Retrieved on: 
Monday, April 8, 2024
Health, Manufacturing, Health Technology, Clinical Trials, Other Manufacturing, Pharmaceutical, Biotechnology, CDMO, Growth, Capsule, Risk, Rheometer, Acquisition, FT4, Senior, Investment, Clinical trial, API, Korsch, Fine chemical

The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.

Key Points: 
  • The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
  • The technology enables rapid transition into first-in-human clinical trial material manufacturing, while also reducing the cost of drug product development.
  • “These tools enable scientists and engineers to rapidly develop life-changing therapies with enhanced data and quality.”
    The expanded capabilities are now available for use.
  • The additional capabilities mark another milestone in the growth of AustinPx’s formulation development and manufacturing offerings, as the Company continues to position itself as a leading CDMO in the pharmaceutical industry.

Sernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting

Retrieved on: 
Friday, September 29, 2023
Thyroid hormones, TSH, American Thyroid Association, Histology, Depression, FSE, ATA, FT4, Quality of life, PSH, Hypothyroidism, Weight gain, Thyroidectomy, Triiodothyronine, Patient, Cell, Annual general meeting, TSX, Poster, Memory, Fatigue, Thyroid, Medical imaging, Pharmaceutical industry

Thyroid stimulating hormone (TSH) levels had a significant peak immediately after thyroidectomy, with a gradual decline observed starting five weeks after the re-implantation of thyroid glands.

Key Points: 
  • Thyroid stimulating hormone (TSH) levels had a significant peak immediately after thyroidectomy, with a gradual decline observed starting five weeks after the re-implantation of thyroid glands.
  • Newly reported radio-isotope uptake imaging and histology assessments confirmed the presence of healthy and functional thyroid tissues within the Cell Pouch six months following re-implantation.
  • “With Sernova’s Cell Pouch System, we aim to improve quality of life with a treatment for post-operative hypothyroidism.
  • These new data replicate a human clinical scenario in which thyroid tissue is reimplanted into the patient, via the Cell Pouch, leading to the restoration of normal thyroid function.

Global Endocrine Testing Market Analysis/Research Report 2022-2027: Tests to Measure Thyroid-Stimulating Hormone (TSH) are Expected to Influence Market Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 28, 2022
Health, Biotechnology, First Nations in Ontario, Triiodothyronine, Androgen deficiency, FT4, Thyroid disease, COVID-19, Roche, University Medical Center Groningen, Thyroid, Department, Geriatrics, ATA, American Thyroid Association, FT3, Incidence, Patient, UN, Tobacco, Growth, Risk, Laboratory, Abbott Laboratories, TT3, Growth hormone, Woman, Smoking, Groningen, CAGR, United Nations, Technology, Serum, Research, University of Groningen, Nephrology, Hypothyroidism, TSH, Menopause, University, Hyperthyroidism, Government, Disease, Endocrine system, Man, Medical device, Vaccine, Pharmaceutical industry, Agriculture

Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.

Key Points: 
  • Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.
  • Since endocrine testing tools are in high demand, market players are more committed to developing new products.
  • The demand for advanced endocrine testing technologies is also expected to grow due to diseases such as hypothyroidism and hyperthyroidism.
  • As a result, the rise in TSH testing is expected to boost market growth for the global endocrine testing market.

New Study Confirms That A Commonly Used Acid-Reducing Drug Does Not Interfere with the Absorption of A Novel Liquid Levothyroxine Formulation

Retrieved on: 
Monday, October 4, 2021
Drug, Tablet, Hypothyroidism, Degenerative disease, Patient, Thyroid, Fatigue, Hair loss, Glycerol, Health, Water, FDA, Depression, GJ, Omeprazole, Constipation, Annual general meeting, Population, TSH, FT4, Thyroid disease, PPI, THE, Virginia Commonwealth University, University, Program, Arch, Internal medicine, Woman, Plasma protein binding, Medicine, Stomach, Absorption, ATA, Forgetting, Weight gain, Health care, Mouth, Cramp, American Thyroid Association, FT3, University of Pisa, IBSA, Pharmaceutical industry

Omeprazole and other PPI medications are powerful acid-reducing agents that are known to affect the performance of traditional levothyroxine treatments that come in tablet form.

Key Points: 
  • Omeprazole and other PPI medications are powerful acid-reducing agents that are known to affect the performance of traditional levothyroxine treatments that come in tablet form.
  • A second group was administered Tirosint-SOL and omeprazole at staggered times Tirosint-SOL in the morning and omeprazole in the evening, 12 hours later.
  • Based on these findings, IBSA Institut Biochimique, the sponsor of the study, is planning to seek FDA approval for a change in the approved label for Tirosint-SOL.
  • 46
    4.Canaris GJ, Manowitz NR, Mayor G, Ridgeway EC, "The Colorado Thyroid Disease Prevalence Study", Arch of Internal Medicine; 2000;160: 526-534
    5.McDermott MT.